This week, hosts Mark Masselli and Margaret Flinter speak with Allan Coukell, Sr. Director for Health Programs at the Pew Charitable Trusts, where he oversees the FDA, drug and medical device safety and the opioid crisis. He discusses suggested changes to the FDA made by the Trump Administration, and how best to promote reforms at the US Food and Drug Administration to better respond to 21st century advances in research and discovery.
Reforming the FDA: Perspectives from the Pew Charitable Trusts

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
This week, hosts Mark Masselli and Margaret Flinter speak with Allan Coukell, Sr. Director for Health Programs at the Pew Charitable Trusts, where he oversees the FDA, drug and medical device safety and the opioid crisis. He discusses suggested changes to the FDA made by the Trump Administration, and how best to promote reforms at the US Food and Drug Administration to better respond to 21st century advances in research and discovery.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
HF Management for Patients with Comorbid Conditions
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?